History of malaria
The history of malaria stretches from its prehistoric origin as a zoonotic disease in the primates of Africa through to the twentieth century. A widespread and potentially lethal human infectious disease, at its peak malaria infested every continent, except Antartica. Its prevention and treatment have been targeted in science and medicine for hundreds of years. Since the discovery of the parasites which cause it, research attention has focused on their biology.
The most critical factors in the spread or eradication of disease have been human behavior (shifting population centers, changing farming methods and the like) and living standards. Precise statistics do not exist because many cases occur in rural areas where people do not have access to hospitals or other health care. As a consequence, the majority of cases are undocumented. Poverty has been and remains associated with the disease.
References to its unique, periodic fevers are found throughout recorded history beginning in 2700 BC in China.
For thousands of years, traditional herbal remedies have been used to treat malaria. The first effective treatment for malaria came from the bark of cinchona tree, which contains quinine. After the link to mosquitos and their parasites were identified in the early twentieth century, mosquito control measures such as widespread use of DDT, swamp drainage, covering or oiling the surface of open water sources, indoor residual spraying and use of insecticide treated nets was initiated. Prophylactic quinine was prescribed in malaria endemic areas, and new therapeutic drugs including chloroquine and artemisinins were used to resist the scourge.
Malaria researchers have won multiple Nobel Prizes for their achievements, although the disease continues to afflict some 200 million patients each year, killing more than 600,000.
Malaria was the most important health hazard encountered by U.S. troops in the South Pacific during World War II, where about 500,000 men were infected. According to Joseph Patrick Byrne, "Sixty thousand American soldiers died of malaria during the African and South Pacific campaigns."
At the close of the 20th century, malaria remains endemic in more than 100 countries throughout the tropical and subtropical zones, including large areas of Central and South America, Hispaniola (Haiti and the Dominican Republic), Africa, the Middle East, the Indian subcontinent, Southeast Asia, and Oceania. Resistance of Plasmodium to anti-malaria drugs, as well as resistance of mosquitos to insecticides and the discovery of zoonotic species of the parasite have complicated control measures.
- 1 Origin and prehistoric period
- 2 Classical period
- 3 Middle Ages
- 4 Spread to the Americas
- 5 19th century
- 6 20th century
- 6.1 Etiology: Plasmodium tissue stage and reproduction
- 6.2 Malariotherapy
- 6.3 Panama Canal and vector control
- 6.4 Antimalarial drugs
- 6.5 Insecticides
- 6.6 Research
- 6.7 A zoonotic malarial parasite
- 7 Notes
- 8 References
- 9 External links
Origin and prehistoric period
The first evidence of malaria parasites was found in mosquitoes preserved in amber from the Palaeogene period that are approximately 30 million years old. Human malaria likely originated in Africa and coevolved with its hosts, mosquitoes and non-human primates. Malaria protozoa are diversified into primate, rodent, bird, and reptile host lineages. Humans may have originally caught Plasmodium falciparum from gorillas. P. vivax, another malarial Plasmodium species among the six that infect humans, also likely originated in African gorillas and chimpanzees. Another malarial species recently discovered to be transmissible to humans, P. knowlesi, originated in Asian macaque monkeys. While P. malariae is highly host specific to humans, there is spotty evidence that low level non-symptomatic infection persists among wild chimpanzees.
About 10,000 years ago malaria started having a major impact on human survival, coinciding with the start of agriculture (Neolithic revolution). Consequences included natural selection for sickle-cell disease, thalassaemias, glucose-6-phosphate dehydrogenase deficiency, Southeast Asian ovalocytosis, elliptocytosis and loss of the Gerbich antigen (glycophorin C) and the Duffy antigen on the erythrocytes, because such blood disorders confer a selective advantage against malaria infection (balancing selection). The three major types of inherited genetic resistance (sickle-cell disease, thalassaemias, and glucose-6-phosphate dehydrogenase deficiency) were present in the Mediterranean world by the time of the Roman Empire, about 2000 years ago.
The introduction of molecular methods confirmed the high prevalence of P.falciparum malaria in ancient Egypt. Ancient historian Herodotus wrote that the builders of the Egyptian pyramids (circa 2700 - 1700 BCE) were given large amounts of garlic, probably to protect them against malaria. Sneferu, the founder of the Fourth dynasty of Egypt, who reigned from around 2613 – 2589 BCE, used bed-nets as protection against mosquitoes. Cleopatra VII, the last Pharaoh of Ancient Egypt, slept under a mosquito net. The presence of malaria in Egypt from circa 800 BCE onwards has been confirmed using DNA-based methodologies.
Malaria became widely recognized in ancient Greece by the 4th century BCE, and is implicated in the decline of many city-state populations. The term μίασμα (Greek for miasma): "stain, pollution", was coined by Hippocrates of Kos who used it to describe dangerous fumes from the ground that are transported by winds and can cause serious illnesses. Hippocrates (460–370 BCE), the "father of medicine", related the presence of intermittent fevers with climatic and environmental conditions and classified the fever according to periodicity: Gk.:tritaios pyretos / L.:febris tertiana (fever every third day), and Gk.:tetartaios pyretos / L.:febris quartana (fever every fourth day).
The Chinese Huangdi Neijing (The Inner Canon of the Yellow Emperor) dating from ~300 BCE - 200 CE apparently refers to repeated paroxysmal fevers associated with enlarged spleens and a tendency to epidemic occurrence. Around 168 BCE the herbal remedy Qing-hao (青蒿) (Artemisia annua) came into use in China to treat female hemorrhoids (Wushi'er bingfang translated as "Recipes for 52 kinds of diseases" unearthed from the Mawangdui tombs). Qing-hao was first recommended for acute intermittent fever episodes by Ge Hong as an effective medication in the 4th-century Chinese manuscript Zhou hou bei ji fang, usually translated as "Emergency Prescriptions kept in one's Sleeve". His recommendation was to soak fresh plants of the artemisia herb in cold water, wring it out and ingest the expressed bitter juice in its raw state.
'Roman fever' (Italian mal'aria) refers to a particularly deadly strain of malaria that affected the Roman Campagna and the city of Rome throughout various epochs in history. An epidemic of Roman fever during the fifth century AD may have contributed to the fall of the Roman empire.
In 835, the celebration of Hallowmas was moved from May to November at the behest of Pope Gregory IV, on the "practical grounds that Rome in summer could not accommodate the great number of pilgrims who flocked to it", and perhaps because of public health considerations regarding Roman Fever, which claimed a number of lives of pilgrims during the sultry summers of the region.
During the Middle Ages, treatments for malaria (and other diseases) included blood-letting, inducing vomiting, limb amputations and trepanning. Some turned to witchcraft and astrology. Physicians and surgeons as well as folk-healers administered ineffective and often deadly herbs - Belladonna, for example.
The name malaria derived from mal aria ('bad air' in Medieval Italian). This idea came from the Ancient Romans who thought that this disease came from the horrible fumes from the swamps. The word malaria has its roots in the miasma theory, as described by historian and chancellor of Florence Leonardo Bruni in his Historiarum Florentini populi libri XII, which was the first major example of Renaissance historical writing:
Avuto i Fiorentini questo fortissimo castello e fornitolo di buone guardie, consigliavano fra loro medesimi fosse da fare. Erano alcuni a' quali pareva sommamente utile e necessario a ridurre lo esercito, e massimamente essendo affaticato per la infermità e per la mala ariae per lungo e difficile campeggiare nel tempo dell'autunno e in luoghi infermi, e vedendo ancora ch'egli era diminuito assai per la licenza conceduta a molti pel capitano di potersi partire: perocchè, nel tempo che eglino erano stati lungamente a quello assedio, molti, o per disagio del campo o per paura d'infermità, avevano domandato e ottenuto licenza da lui.
After the Florentines had conquered this stronghold, after putting good guardians on it they were discussing among themselves how to proceed. For some of them it appeared most useful and necessary to reduce the army, more so as it was extremely stressed by disease and bad air, and due to the long-lasting and difficult camps in unhealthy places during the autumn. They (the Florentines) further considered that the army was reduced in numbers due to the leave permits granted to many soldiers by the officers. In fact during the siege many soldiers had asked and obtained the permit to leave due to the camp hardships and fear of illness (Leonardo Bruni, 1444) [translated from medieval Italian].
The coastal plains of southern Italy fell from international prominence when malaria expanded in the sixteenth century. At roughly the same time, in the coastal marshes of England, mortality from "marsh fever" or "tertian ague" (ague: via French from medieval Latin acuta (febris), acute fever) was comparable to that in sub-Saharan Africa today. William Shakespeare was born at the start of the especially cold period that climatologists call the "Little Ice Age", yet he was aware enough of the ravages of the disease to mention it in eight of his plays.
Medical accounts and ancient autopsy reports state that tertian malarial fevers caused the death of four members of the prominent Medici family of Florence [Note 1]. These claims have been confirmed with more modern methodologies.
Spread to the Americas
Spanish missionaries found that fever was treated by Amerindians near Loxa (Peru) with powder from Peruvian bark (later established to be from any of several trees of genus Cinchona). It was used by the Quechua Indians of Peru to reduce the shaking effects caused by severe chills. Jesuit Brother Agostino Salumbrino (1561–1642), an apothecary by training and who lived in Lima, observed the Quechua using the bark of the cinchona tree for that purpose. While its effect in treating malaria (and hence malaria-induced shivering) was unrelated to its effect in controlling shivering from cold, it was nevertheless effective for malaria. The use of the “fever tree” bark was introduced into European medicine by Jesuit missionaries (Jesuit's bark). Jesuit Barnabé de Cobo (1582–1657), who explored Mexico and Peru, is credited with taking cinchona bark to Europe. He brought the bark from Lima to Spain, and then to Rome and other parts of Italy, in 1632. Francesco Torti wrote in 1712 that only “intermittent fever” was amenable to the fever tree bark. This work finally established the specific nature of cinchona bark and brought about its general use in medicine.
It would be nearly 200 years before the active principals, quinine and other alkaloids, of cinchona bark were isolated. Quinine, a toxic plant alkaloid, in addition to its anti-malarial properties, is an effective muscle relaxant, as the modern use for nocturnal leg cramps suggests (corroborating its use for shivering by the Peruvian Indians).
In 1717, the dark pigmentation of a postmortem spleen and brain was published by the epidemiologist Giovanni Maria Lancisi in his malaria text book De noxiis paludum effluviis eorumque remediis. This was one of the earliest reports of the characteristic enlargement of the spleen and dark color of the spleen and brain which are the most constant post-mortem indications of chronic malaria infection. He related the prevalence of malaria in swampy areas to the presence of flies and recommended swamp drainage to prevent it.
In the nineteenth century, the first drugs were developed to treat malaria and parasites were first identified as its source.
French chemist Pierre Joseph Pelletier and French pharmacist Joseph Bienaimé Caventou separated in 1820 the alkaloids cinchonine and quinine from powdered fever tree bark, allowing for the creation of standardized doses of the active ingredients. Prior to 1820, the bark was simply dried, ground to a fine powder and mixed into a liquid (commonly wine) for drinking.
An English trader, Charles Ledger, and his Amerindian servant spent four years collecting cinchona seeds in the Andes in Bolivia, highly prized for their quinine but whose export was prohibited. Ledger managed to get seeds out; in 1865 the Dutch government cultivated 20,000 trees of the Cinchona ledgeriana in Java (Indonesia). By the end of the nineteenth century the Dutch had established a world monopoly over its supply.
In 1834, in British Guiana, a German physician, Carl Warburg, invented an antipyretic medicine: 'Warburg's Tincture'. This secret, proprietary remedy contained quinine and other herbs. Trials were made in Europe in the 1840s and 1850s. It was officially adopted by the Austrian Empire in 1847. It was considered by many eminent medical professionals to be a more efficacious antimalarial than quinine. It was also more economical. The British Government supplied Warburg's Tincture to troops in India and other colonies.
In 1876, methylene blue was synthesized by German chemist Heinrich Caro. Paul Ehrlich in 1880 described the use of "neutral" dyes – mixtures of acidic and basic dyes for the differentiation of cells in peripheral blood smears. In 1891 Ernst Malachowski and Dmitri Leonidovich Romanowsky independently developed techniques using a mixture of Eosin Y and modified methylene blue (methylene azure) that produced a surprising hue unattributable to either staining component: a shade of purple. Malachowski used alkali-treated methylene blue solutions and Romanowsky used methylene blue solutions which were molded or aged. This new method differentiated blood cells and demonstrated the nuclei of malarial parasites. Malachowski's staining technique was one of the most significant technical advances in the history of malaria.
In 1891, Paul Guttmann and Ehrlich noted that methylene blue had a high affinity for some tissues and that this dye had a slight antimalarial property. Methylene blue and its congeners may act by preventing the biocrystallization of heme.
Etiology: Identification of Plasmodium and Anopheles
IN 1848 German anatomist Johann Heinrich Meckel recorded black-brown pigment granules in the blood and spleen of a patient who had died in a mental hospital. Meckel was thought to have been looking at malaria parasites without realizing it; he did not mention malaria in his report. He hypothesized that the pigment was melanin. The causal relationship of pigment to the parasite was established in 1880, when French physician Charles Louis Alphonse Laveran, working in the military hospital of Constantine, Algeria, observed pigmented parasites inside the red blood cells of malaria sufferers. He witnessed the events of exflagellation and became convinced that the moving flagella were parasitic microorganisms. He noted that quinine removed the parasites from the blood. Laveran called this microscopic organism Oscillaria malariae and proposed that malaria was caused by this protozoan. This discovery remained controversial until the development of the oil immersion lens in 1884 and of superior staining methods in 1890–1891.
In 1885, Ettore Marchiafava, Angelo Celli and Camillo Golgi studied the reproduction cycles in human blood (Golgi cycles). Golgi observed that all parasites present in the blood divided almost simultaneously at regular intervals and that division coincided with attacks of fever. In 1886 Golgi described the morphological differences that are still used to distinguish two malaria parasite species Plasmodium vivax and Plasmodium malariae. Shortly after this Sakharov in 1889 and Marchiafava & Celli in 1890 independently identified Plasmodium falciparum as a species distinct from P. vivax and P. malariae. In 1890, Grassi and Feletti reviewed the available information and named both P. malariae and P. vivax (although within the genus Haemamoeba.) By 1890 Laveran's germ was generally accepted, but most of his initial ideas had been discarded in favor of the taxonomic work and clinical pathology of the Italian school. Marchiafava and Celli called the new microorganism Plasmodium. H. vivax was soon renamed Plasmodium vivax. In 1892 Marchiafava and Bignami proved that the multiple forms seen by Laveran were from a single species. This species was eventually named P. falciparum. Laveran was awarded the 1907 Nobel Prize for Physiology or Medicine "in recognition of his work on the role played by protozoa in causing diseases".
Dutch physician Pieter Pel first proposed a tissue stage of the malaria parasite in 1886, presaging its discovery by over 50 years. This suggestion was reiterated in 1893 when Golgi suggested that the parasites might have an undiscovered tissue phase (this time in endothelial cells). Pel in 1896 supported Gogli's latent phase theory.
The establishment of the scientific method from about the mid-19th century on demanded testable hypotheses and verifiable phenomena for causation and transmission. Anecdotal reports[Note 2], and the discovery in 1881 that mosquitos were the vector of Yellow fever, eventually led to the investigation of mosquitos in connection with malaria.
An early effort at malaria prevention occurred in 1896 in Masssachusetts. An Uxbridge outbreak prompted health officer Dr. Leonard White to write a report to the State Board of Health, which led to a study of mosquito-malaria links and the first efforts for malaria prevention. Massachusetts state pathologist, Theobald Smith, asked that White's son collect mosquito specimens for further analysis, and that citizens add screens to windows, and drain collections of water.
Britain's Sir Ronald Ross, an army surgeon working in Secunderabad India, proved in 1897 that malaria is transmitted by mosquitoes, an event now commemorated via World Mosquito Day. He was able to find pigmented malaria parasites in a mosquito that he artificially fed on a malaria patient who had crescents in his blood. He continued his research into malaria by showing that certain mosquito species (Culex fatigans) transmit malaria to sparrows and he isolated malaria parasites from the salivary glands of mosquitoes that had fed on infected birds. He reported this to the British Medical Association in Edinburgh in 1898.
Giovanni Battista Grassi, professor of Comparative Anatomy at Rome University, showed that human malaria could only be transmitted by Anopheles (Greek anofelís: good-for-nothing) mosquitoes. Grassi along with coworkers Amico Bignami, Giuseppe Bastianelli and Ettore Marchiafava announced at the session of the Accademia dei Lincei on 4 December 1898 that a healthy man in a non-malarial zone had contracted tertian malaria after being bitten by an experimentally infected Anopheles claviger specimen.
In 1898-99 Bastianelli, Bignami and Grassi were the first to observe the complete transmission cycle of P. falciparum, P. vivax and P. malariae from mosquito to human and back in A. claviger.
A dispute broke out between the British and Italian schools of malariology over priority, but Ross received the 1902 Nobel Prize for Physiology or Medicine for "his work on malaria, by which he has shown how it enters the organism and thereby has laid the foundation for successful research on this disease and methods of combating it".
Synthesis of quinine
William Henry Perkin, a student of August Wilhelm von Hofmann at the Royal College of Chemistry in London, unsuccessfully tried in the 1850s to synthesize quinine in a commercial process. The idea was to take two equivalents of N-allyltoluidine (C
13N) and three atoms of oxygen to produce quinine (C
2) and water. Instead, Perkin's mauve was produced when attempting quinine total synthesis via the oxidation of N-allyltoluidine. Before Perkin's discovery, all dyes and pigments were derived from roots, leaves, insects, or, in the case of Tyrian purple, molluscs.
Quinine wouldn't be successfully synthesized until 1918. Synthesis remains elaborate, expensive and low yield, with the additional problem of separation of the stereoisomers. Though quinine is not one of the major drugs used in treatment, modern production still relies upon extraction from the cinchona tree.
Etiology: Plasmodium tissue stage and reproduction
Relapses were first noted in 1897 by William S. Thayer, who recounted the experiences of a physician who relapsed 21 months after leaving an endemic area. He proposed the existence of a tissue stage. Relapses were confirmed by Patrick Manson, who allowed infected Anopheles mosquitoes to feed on his eldest son. The younger Manson then described a relapse nine months after his apparent cure with quinine.
Also in 1900 Amico Bignami and Giuseppe Bastianelli found that they could not infect an individual with blood containing only gametocytes. The possibility of the existence of a chronic blood stage infection was proposed by Ronald Ross and David Thompson in 1910.
The existence of asexually-reproducing avian malaria parasites in cells of the internal organs was first demonstrated by Henrique de Beaurepaire Aragão in 1908.
Three possible mechanisms of relapse were proposed by Marchoux in 1926 (
i) parthenogenesis of macrogametocytes: (
ii) persistence of schizonts in small numbers in the blood where immunity inhibits multiplication, but later disappears and/or (
iii) reactivation of an encysted body in the blood. James in 1931 proposed that sporozoites are carried to internal organs, where they enter reticuloendothelial cells and undergo a cycle of development, based on quinine's lack of activity on them. Huff and Bloom in 1935 demonstrated stages of avian malaria that transpire outside blood cells (exoerythrocytic). In 1945 Fairley et al. reported that inoculation of blood from a patient with P. vivax may fail to induce malaria, although the donor may subsequently exhibit the condition. Sporozoites disappeared from the blood stream within one hour and reappeared eight days later. This suggested the presence of forms that persist in tissues. Using mosquitoes rather than blood, in 1946 Shute described a similar phenomenon and proposed the existence of an 'x-body' or resting form. The following year Sapero proposed a link between relapse and a tissue stage not yet discovered. Garnham in 1947 described exoerythrocytic schizogony in Hepatocystis (Plasmodium) kochi. In the following year Shortt and Garnham described the liver stages of P. cynomolgi in monkeys. In the same year a human volunteer consented to receive a massive dose of infected sporozoites of P. vivax and undergo a liver biopsy three months later, thus allowing Shortt et al. to demonstrate the tissue stage. The tissue form of Plasmodium ovale was described in 1954 and that of P. malariae in 1960 in experimentally infected chimpanzees.
The latent or dormant liver form of the parasite (hypnozoite), responsible for the late relapses characteristic of P. vivax and P. ovale infections, was observed in the 1980s. The term hypnozoite was coined by Miles B. Markus while a student. In 1976, he speculated: "If sporozoites of Isospora can behave in this fashion, then those of related Sporozoa, like malaria parasites, may have the ability to survive in the tissues in a similar way." In 1982 Krotoski et al report identification of P. vivax hypnozoites in liver cells of infected chimpanzees.
In the early twentieth century, before antibiotics, patients with tertiary syphilis were intentionally infected with malaria to create a fever; this was called malariotherapy. In 1917 Julius Wagner-Jauregg, a Viennese psychiatrist, began to treat neurosyphilitics with induced Plasmodium vivax malaria. Three or four bouts of fever were enough to kill the temperature-sensitive syphilis bacteria (Spirochaeta pallida also known as Treponema pallidum). P. vivax infections were terminated by quinine. By accurately controlling the fever with quinine, the effects of both syphilis and malaria could be minimized. While about 15% of patients died from malaria, this was preferable to the almost-certain death from syphilis. Therapeutic malaria opened up a wide field of chemotherapeutic research and was practised until 1950. Wagner-Jauregg was awarded the 1927 Nobel Prize in Physiology or Medicine for his discovery of the therapeutic value of malaria inoculation in the treatment of dementia paralytica.
Maliariothrapy has been advocated as a therapy for AIDS by Henry Heimlich. and some studies of malariotherapy for HIV infection have been performed in China. The CDC does not recommend the use of malariotherapy for HIV.
Panama Canal and vector control
In 1881, Dr. Carlos Finlay, a Scottish physician practising in Havana, theorized that yellow fever was transmitted by a specific mosquito, later designated Aedes aegypti. The theory remained controversial for twenty years until confirmed in 1901 by Walter Reed. This was the first scientific proof of a disease being transmitted exclusively by an insect vector, and demonstrated that control of such diseases necessarily entailed control or eradication of its insect vector.
Johann "Hans" Andersag and colleagues synthesized and tested some 12,000 compounds, eventually producing Resochin® as a substitute for quinine in the 1930s. It is chemically related to quinine through the possession of a quinoline nucleus and the dialkylaminoalkylamino side chain. Resochin (7-chloro-4- 4- (diethylamino) – 1 – methylbutyl amino quinoline) and a similar compound Sontochin (3-methyl Resochin) were synthesized in 1934. In March 1946 the drug was officially named Chloroquine. Chloroquine is an inhibitor of hemozoin production through biocrystallization. Quinine and chloroquine affect malarial parasites only at life stages when the parasites are forming hematin-pigment (hemozoin) as a byproduct of hemoglobin degradation. Chloroquine-resistant forms of P. falciparum emerged only 19 years later. The first resistant strains were detected around the Cambodia‐Thailand border and in Colombia, in the 1950s. In 1989 chloroquine resistance in P. vivax was reported in Papua New Guinea. These resistant strains spread rapidly, producing a large mortality increase, particularly in Africa during the 1990s.
Systematic screening of traditional Chinese medical herbs was carried out by Chinese research teams, consisting of hundreds of scientists in the 1960s and 1970s. Qinghaosu, later named artemisinin, was cold-extracted in a neutral milieu (pH 7.0) from the dried leaves of Artemisia annua.
Artemisinin was isolated by pharmacologist Tu Youyou. Tu headed a team tasked by the Chinese government with finding a treatment for choloroquine-resistant malaria. Their work was known as Project 523, named after the date it was announced – 23 May 1967. The team investigated more than 20,00 Chinese herb preparations and by 1971 had made 380 extracts from 200 herbs. An extract from qinghao (Artemisia annua) was effective but the results were variable. Tu reviewed the literature, including Zhou hou bei ji fang (A handbook of prescriptions for emergencies) written in 340 BC by Chinese physician Ge Hong. This book contained the only useful reference to the herb: "A handful of qinghao immersed with two litres of water, wring out the juice and drink it all." Tu's team subsequently isolated a nontoxic, neutral extract that was 100% effective against parasitemia in animals. The first successful trials of artemisinin were in 1979.
Artemisinin is a sesquiterpene lactone containing a peroxide group, which is believed to be essential for its anti-malarial activity. Its derivatives, artesunate and artemether, have been used in clinics since 1987 for the treatment of drug-resistant and drug-sensitive malaria, especially cerebral malaria. These drugs are characterized by fast action, high efficacy and good tolerance. They kill the asexual forms of P. berghei and P. cynomolgi and have transmission-blocking activity. In 1985, Zhou Yiqing and his team combined artemether and lumefantrine into a single tablet, which was registered as a medicine in China in 1992. Later it became known as “Coartem”. Artemisinin combination treatments (ACTs) are now widely used to treat uncomplicated falciparum malaria, but access to ACTs is still limited in most malaria-endemic countries and only a minority of the patients who need artemisinin-based combination treatments receive them.
Efforts to control the spread of malaria suffered a major setback in 1930. Entomologist Raymond Corbett Shannon discovered imported disease-bearing Anopheles gambiae mosquitoes living in Brazil (DNA analysis later revealed the actual species to be A. arabiensis). This species of mosquito is a particularly efficient vector for malaria and is native to Africa. In 1938, the introduction of this vector caused the greatest epidemic of malaria ever seen in the New World. However, complete eradication of A.gambiae from northeast Brazil and thus from the New World was achieved in 1940 by meticulous application of Paris Green to breeding places and of Pyrethrum spray-killing to adult resting places.
Austrian chemist Othmar Zeidler is credited with the first synthesis of DDT (DichloroDiphenylTrichloroethane) in 1874. The insecticidal properties of DDT were identified in 1939 by chemist Paul Hermann Müller of Geigy Pharmaceutical. For his discovery of DDT as a contact poison against several arthropods, he was awarded the 1948 Nobel Prize in Physiology or Medicine. In the fall of 1942, samples of the chemical were acquired by the United States, Britain and Germany. Laboratory tests demonstrated that it was highly effective against many insects.
Rockefeller Foundation studies showed in Mexico that DDT remained effective for six to eight weeks if sprayed on the inside walls and ceilings of houses and other buildings. The first field test in which residual DDT was applied to the interior surfaces of all habitations and outbuildings was carried out in central Italy in the spring of 1944. The objective was to determine the residual effect of the spray upon Anopheline density in the absence of other control measures. Spraying began in Castel Volturno and, after a few months, in the delta of the Tiber. The unprecedented effectiveness of the chemical was confirmed: the new insecticide was able to eradicate malaria by eradicating mosquitoes. At the end of World War II a massive malaria control program based on DDT spraying was carried out in Italy. In Sardinia – the second largest island in the Mediterranean – between 1946 and 1951, the Rockefeller Foundation conducted a large-scale experiment to test the feasibility of the strategy of "species eradication" in an endemic malaria vector. Malaria was effectively eliminated in the United States by the use of DDT in the National Malaria Eradication Program (1947–52). The concept of eradication prevailed in 1955 in the Eighth World Health Assembly: DDT was adopted as a primary tool in the fight against malaria.
In 1953, the World Health Organization (WHO) launched an antimalarial program in parts of Liberia as a pilot project to determine the feasibility of malaria eradication in tropical Africa. However these projects encountered difficulties that foreshadowed the general retreat from malaria eradication efforts across tropical Africa by the mid-1960s.
DDT was banned in the US in 1972, after the discussion opened in 1962 by Silent Spring, written by American biologist Rachel Carson, which launched the environmental movement in the West. The book catalogued the environmental impacts of indiscriminate DDT spraying and suggested that DDT and other pesticides cause cancer and that their agricultural use was a threat to wildlife. The U.S. Agency for International Development supports indoor DDT spraying as a vital component of malaria control programs and has initiated DDT and other insecticide spraying programs in tropical countries.
Other insecticides are available for mosquito control in addition to measures such as draining of wetland breeding grounds and provision of better sanitation. Pyrethrum (Chrysanthemum [or Tanacetum ] cinerariaefolium) is an economically important source of natural insecticide. Pyrethrins attack the nervous systems of all insects. A few minutes after application the insect cannot move or fly, while female mosquitoes are inhibited from biting. The use of pyrethrum in insecticide preparations dates to about 400 BCE. Pyrethrins are biodegradable and break down easily on exposure to light. The majority of the world's supply of pyrethrin and Chrysanthemum cinerariaefolium comes from Kenya. The flower was first introduced into Kenya and the highlands of Eastern Africa during the late 1920s. The flowers of the plant are harvested shortly after blooming and are either dried and powdered or the oils within the flowers are extracted with solvents.
Avian, mouse and monkey models
Until the 1950s screening of anti-malarial drugs was carried out on avian malaria. Avian malaria species differ from those that infect humans. The discovery in 1948 of Plasmodium berghei in wild rodents in the Congo and later other rodent species that could infect laboratory rats transformed drug development. The short hepatic phase and life cycle of these parasites made them useful as animal models, a status they still retain. Plasmodium cynomolgi in Rhesus monkeys (Macaca mulatta) were used in the 1960s to test drugs active against P. vivax.
Growth of the liver stages in animal-free systems was achieved in the 1980s when pre-erythrocytic P. berghei stages were grown in wI38, a human embryonic lung cell line (cells cultured from one specimen). This was followed by their growth in human hepatoma line HepG2. Both P. falciparum and P. vivax have been grown in human liver cells; partial development of P. ovale in human liver cells was achieved; and P. malariae was grown in chimpanzee and monkey liver cells.
The first successful continuous malaria culture was established in 1976 by William Trager and James B. Jensen, which facilitated research into the molecular biology of the parasite and the development of new drugs. By using increasing volumes of culture medium, P.falciparum was grown to higher parasitemia levels (above 10%).
The use of antigen-based malaria rapid diagnostic tests (RDTs) emerged in the 1980s. In the twenty-first century Giemsa microscopy and RDTs became the two preferred diagnostic techniques. Malaria RDTs do not require special equipment and offer the potential to extend accurate malaria diagnosis to areas lacking microscopy services.
A zoonotic malarial parasite
Plasmodium knowlesi has been known since the 1930s in Asian macaque monkeys and as experimentally capable of infecting humans. In 1965 a natural human infection was reported in a U.S. soldier returning from the Pahang Jungle of the Malaysian peninsula.
- Eleonora of Toledo (1522–1562), Cardinal Giovanni (1543–1562), Don Garzia (1547–1562) and Grand Duke Francesco I (1531–1587)
- Giovanni Maria Lancisi, John Crawford, Patrick Manson, Josiah C. Nott, Albert Freeman Africanus King and Laveran developed theories that malaria was caused by mosquito bites, but little evidence supported this idea.
- Carter R, Mendis KN (2002). "Evolutionary and historical aspects of the burden of malaria". Clin Microbiol Rev 15 (4): 564–94. PMC 126857. PMID 12364370.
- Cox FE (2010). "History of the discovery of the malaria parasites and their vectors". Parasites & Vectors 3: 5.
- Breman J (2001). "The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden". Am J Trop Med Hyg 64 (1–2 Suppl): 1–11. PMID 11425172.
- Worrall E, Basu S, Hanson K (2005). "Is malaria a disease of poverty? A review of the literature". Trop Med Int Health. 10 (10): 1047–59. doi:10.1111/j.1365-3156.2005.01476.x. PMID 16185240.
- Neghina R, Neghina AM, Marincu I, Iacobiciu I (2010). "Malaria, a Journey in Time: In Search of the Lost Myths and Forgotten Stories". Am J Med Sci 340 (6): 492–498. doi:10.1097/MAJ.0b013e3181e7fe6c. PMID 20601857.
- Willcox ML, Bodeker G (2004). "Traditional herbal medicines for malaria". BMJ 329 (7475): 1156–9. doi:10.1136/bmj.329.7475.1156. PMC 527695. PMID 15539672.
- Bray RS (2004). Armies of Pestilence: The Effects of Pandemics on History. James Clarke. p. 102. ISBN 978-0-227-17240-7.
- Byrne JP (2008). Encyclopedia of Pestilence, Pandemics, and Plagues: A-M. ABC-CLIO. p. 383. ISBN 978-0-313-34102-1.
- Poinar G (2005). "Plasmodium dominicana n. sp. (Plasmodiidae: Haemospororida) from Tertiary Dominican amber". Syst. Parasitol. 61 (1): 47–52. doi:10.1007/s11230-004-6354-6. PMID 15928991.
- Joy DA, Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, Suh E, Beerli P, Su XZ. (2003). "Early origin and recent expansion of Plasmodium falciparum". Science 300 (5617): 318–21. doi:10.1126/science.1081449. PMID 12690197.
- Hayakawa T, Culleton R, Otani H, Horii T, Tanabe K (2008). "Big bang in the evolution of extant malaria parasites". Mol Biol Evol 25 (10): 2233–9. doi:10.1093/molbev/msn171. PMID 18687771.
- Liu W, Li Y, Learn GH, Rudicell RS, Robertson JD, Keele BF, Ndjango J-BN, Sanz CM, Morgan DB, Locatelli S, Gonder MK, Kranzusch PJ, Walsh PD, Delaporte E, Mpoudi-Ngole E, Georgiev AV, Muller MN, Shaw GW, Peeters M, Sharp PM, Julian C. Rayner JC & Hahn BH (2010). "Origin of the human malaria parasite Plasmodium falciparum in gorillas". Nature 467 (7314): 420–5. doi:10.1038/nature09442. PMC 2997044. PMID 20864995.
- Liu W et.al. (21 February 2014). "African origin of the malaria parasite Plasmodium vivax". Nature Communications (5).
- Lee KS, Divis PC, Zakaria SK, Matusop A, Julin RA, Conway DJ, Cox-Singh J, Singh B (2011). "Plasmodium knowlesi: reservoir hosts and tracking the emergence in humans and macaques.". PLoS Pathog (7).
- Hayakawa, Toshiyuki; et.al. (2009). Identification of Plasmodium malariae, a human malaria parasite, in imported chimpanzees 4 (10). doi:10.1371/journal.pone.0007412.
- Canali S (2008). "Researches on thalassemia and malaria in Italy and the origins of the "Haldane hypothesis"". Med Secoli 20 (3): 827–46. PMID 19848219.
- Sallares R, Bouwman A, Anderung C (2004). "The Spread of Malaria to Southern Europe in Antiquity: New Approaches to Old Problems". Med Hist 48 (3): 311–28. PMC 547919. PMID 16021928.
- Brier B (2004). "Infectious diseases in ancient Egypt". Infect Dis Clin North Am 18 (1): 17–27. doi:10.1016/S0891-5520(03)00097-7. PMID 15081501.
Nerlich AG, Schraut B, Dittrich S, Jelinek T, Zink AR. (2008). "Plasmodium falciparum in Ancient Egypt". Emerg Infect Dis 14 (8): 1317–9. doi:10.3201/eid1408.080235. PMC 2600410. PMID 18680669.
- Macaulay GC (1890). The History of Herodotus, parallel English/Greek translation. pp. Herodotus, 2.125.
- "History of Malaria Control". Retrieved 2009-10-27.
- Lalremruata A, Ball M, Bianucci R, Welte B, Nerlich AG, Kun JF, Pusch CM. "Molecular identification of falciparum malaria and human tuberculosis co-infections in mummies from the Fayum depression (lower Egypt)". PLoS One 8(4):e60307. PMC 3614933.
- Li Y, Wu YL. (2003). "An over four millennium story behind qinghaosu (artemisinin)--a fantastic antimalarial drug from a traditional Chinese herb". Curr Med Chem 10 (21): 2197–230. doi:10.2174/0929867033456710. PMID 14529339.
- Hippocrates. Of the epidemics (Translated by Francis Adams) The Internet Classics Archive.
Pappas G, Kiriaze IJ, Falagas ME (2008). "Insights into infectious disease in the era of Hippocrates". Int J Infect Dis. 12 (4): 347–50. doi:10.1016/j.ijid.2007.11.003. PMID 18178502.
- Cox F (2002). "History of Human Parasitology". Clin Microbiol Rev 15 (4): 595–612. doi:10.1128/CMR.15.4.595-612.2002. PMC 126866. PMID 12364371.
- Wright CW, Linley PA, Brun R, Wittlin S, Hsu E (2010). "Ancient chinese methods are remarkably effective for the preparation of artemisinin-rich extracts of qing hao with potent antimalarial activity". Molecules 15 (2): 804–12. doi:10.3390/molecules15020804. PMID 20335947.
- Hsu E (2006). "Reflections on the 'discovery' of the antimalarial qinghao". Br J Clin Pharmacol 61 (6): 666–70. doi:10.1111/j.1365-2125.2006.02673.x. PMC 1885105. PMID 16722826.
- Li Y, Wu YL. (1998). "How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives?". Med Trop (Mars) 58 (3 Suppl): 9–12. PMID 10212890.
- Sallares R (2002). "Malaria and Rome: a history of malaria in ancient Italy". Oxford University Press.
- Butler's Saint for the Day (Paul Burns), Liturgical Press, page 516
- Hempelmann E, Krafts K (2013). "Bad air, amulets and mosquitoes: 2,000 years of changing perspectives on malaria". Malar J. 12 (1): 213. doi:10.1186/1475-2875-12-232. PMID 23835014.
- Dobson MJ (1994). "Malaria in England: a geographical and historical perspective". Parassitologia. 36 (1–2): 35–60. PMID 7898959.
Knottnerus O S (2002). "Malaria Around the North Sea: A Survey". Gerold Wefer, Wolfgang H. Berger, Karl-Ernst Behre, Eynstein Jansen (ed.), Climatic Development and History of the North Atlantic Realm: Hanse Conference Report. Springer-Verlag: 339–353.
- Reiter P (2000). "From Shakespeare to Defoe: malaria in England in the Little Ice Age". Emerg Infect Dis. 6 (1): 1–11. doi:10.3201/eid0601.000101. PMC 2627969. PMID 10653562.
- Fornaciari G, Giuffra V, Ferroglio E, Gino S, Bianucci R (2010). "Plasmodium falciparum immunodetection in bone remains of members of the Renaissance Medici family (Florence, Italy, sixteenth century)". Trans R Soc Trop Med Hyg 104 (9): 583–7. doi:10.1016/j.trstmh.2010.06.007. PMID 20673935.
- De Castro MC, Singer BH (2005). "Was malaria present in the Amazon before the European conquest? Available evidence and future research agenda". J Achaeol Sci 32 (3): 337–340. doi:10.1016/j.jas.2004.10.004.
- Yalcindag E, Elguero E, Arnathau C, Durand P, Akiana J, Anderson TJ, Aubouy A, Balloux F, Besnard P, Bogreau H, Carnevale P, D'Alessandro U, Fontenille D, Gamboa D, Jombart T, Le Mire J, Leroy E, Maestre A, Mayxay M, Ménard D, Musset L, Newton PN, Nkoghé D, Noya O, Ollomo B, Rogier C, Veron V, Wide A, Zakeri S, Carme B, Legrand E, Chevillon C, Ayala FJ, Renaud F, Prugnolle F (2011). "Multiple independent introductions of Plasmodium falciparum in South America". PNAS 109 (2): 511–6. doi:10.1073/pnas.1119058109. PMC 3258587. PMID 22203975.
- Butler AR, Khan S, Ferguson E (2010). "A brief history of malaria chemotherapy". J R Coll Physicians Edinb 40 (2): 172–7. doi:10.4997/JRCPE.2010.216. PMID 20695174.
- Guerra F. (1977). "The introduction of Cinchona in the treatment of malaria". J Trop Med Hyg. 80 (6): 112–118; 135–140. PMID 330870.
- Greenwood D. (1992). "The quinine connection". J Antimicrob Chemother. 30 (4): 417–27. doi:10.1093/jac/30.4.417. PMID 1490916.
Kaufman T, Rúveda E (2005). "The quest for quinine: those who won the battles and those who won the war". Angew Chem Int Ed Engl 44 (6): 854–85. doi:10.1002/anie.200400663. PMID 15669029.
- Torti, F. “Therapeutice Specialis ad Febres Periodicas Perniciosas”, 1712 Modena
- Bruce-Chwatt LJ (1988). "Three hundred and fifty years of the Peruvian fever bark". Br Med J (Clin Res Ed) 296 (6635): 1486–7. doi:10.1136/bmj.296.6635.1486. PMC 2546010. PMID 3134079.
- Guay DR (2008). "Are there alternatives to the use of quinine to treat nocturnal leg cramps?". Consult Pharm 23 (2): 141–56. doi:10.4140/TCP.n.2008.141. PMID 18454580.
- Cook GC, Webb AJ. (2000). "Perceptions of malaria transmission before Ross' discovery in 1897". Postgrad Med J. 76 (901): 738–40.
- Pelletier and Caventou (1820) "Suite: Des recherches chimiques sur les quinquinas" (Continuation: Chemical research on quinquinas), Annales de Chimie et de Physique, vol. 15, pages 337–365. The authors name quinine on page 348: "..., nous avons cru devoir la nommer quinine, pour la distinguer de la cinchonine par un nom qui indique également son origine." (..., we thought that we should name it "quinine" in order to distinguish it from cinchonine by means of a name that also indicates its origin.)
Kyle RA, Shampe MA (1974). "Discoverers of quinine". JAMA 229 (4): 462. doi:10.1001/jama.229.4.462. PMID 4600403.
- Siegel RE, Poynter FN (1962). "Robert Talbor, Charles II, and cinchona: a contemporary document". Med Hist 6 (1): 82–5. PMC 1034677. PMID 16562233.
- Gramiccia G (1987). "Ledger's cinchona seeds: a composite of field experience, chance, and intuition". Parassitologia 29 (2–3): 207–20. PMID 3334083.
- Maclean WC (1875). "Professor Maclean, C.B., on the true composition and therapeutic value of Warburg's Tincture". Lancet 106 (2724): 716–718. doi:10.1016/S0140-6736(02)30835-3.
Poser CM, Bruyn GW. (1999). "An Illustrated History of Malaria, p. 87". New York: Parthenon, ISBN 978-1-85070-068-5 (Informa Health Care). ISBN 978-1-85070-068-5.
- Krafts K, Hempelmann E, Oleksyn BJ (2011). "In search of the malarial parasite : Biographical sketches of the blood stain contributors". Parasitol Research 109 (3): 521–529. doi:10.1007/s00436-011-2475-4. PMID 21660627.
- Malachowski E (1891). "Zur Morphologie des Plasmodium malariae". Centbl f klin Med 31: 601–603.
- Romanowsky D (1891). "Zur Frage der Parasitologie und Therapie der Malaria". St Petersburg Med Wochenschr 16: 297–302, 307–315.
- Horobin RW, Walter KJ (1987). "Understanding Romanowsky staining. I: The Romanowsky-Giemsa effect in blood smears". Histochemistry 86 (3): 331–6. PMID 2437082.
Woronzoff-Dashkoff KK. (2002). "The wright-giemsa stain. Secrets revealed". Clin Lab Med. 22 (1): 15–23. doi:10.1016/S0272-2712(03)00065-9. PMID 11933573.
- Krafts KP, Hempelmann E, Oleksyn B (2011). "The color purple: from royalty to laboratory, with apologies to Malachowski". Biotech Histochem 86 (1): 7–35. doi:10.3109/10520295.2010.515490. PMID 21235291.
- Guttmann P, Ehrlich P (1891). "Ueber die Wirkung des Methylenblau bei Malaria". Berliner Klinische Wochenschrift 28: 953–956.
- Wainwright M, Amaral L (2005). "The phenothiazinium chromophore and the evolution of antimalarial drugs". Trop Med Int Health 10 (6): 501–11. doi:10.1111/j.1365-3156.2005.01417.x. PMID 15941412.
- Laveran CLA (1880). "Note sur un nouveau parasite trouvé dans le sang de plusieurs malades atteints de fièvre palustres". Bull Acad Med 9: 1235–1236.
- Lorber CG, Lorber CP, Schneider J (2005). "Die Medizinerfamilie Meckel aus Wetzlar". Hess Aerzteblatt 2: 95–99.
- Meckel H. (1847). "Ueber schwarzes Pigment in der Milz und dem Blute einer Geisteskranken". Zeitschrift für Psychiatrie IV: 198–226.
- Cox FE (2010). "History of the discovery of the malaria parasites and their vectors". Parasites & Vectors 3 (1): 5. doi:10.1186/1756-3305-3-5. PMC 2825508. PMID 20205846.
- Grassi, B; Feletti, R (1890). "Parasites malariques chez les oiseaux.". Arch. Ital. Biol. 13: 297–300.
- Smith DC, Sanford LB. (1985). "Laveran's germ: the reception and use of a medical discovery". Am J Trop Med Hyg 34 (1): 2–20. PMID 2578751.
- "Biography of Alphonse Laveran". The Nobel Foundation. Retrieved 2007-06-15.
- Golgi C (1893). "Sulle febbri malariche estivo-autumnali di Roma". Gass Med di Pavia 2: 481–493, 505–520, 529–544, 553–559.
- Pel PK (1886). "Mededeelingen uit de Geneeskundige kliniek. Malaria infectie". Ned Tijdschr Geneeskd 22: 341–358.
- Doetsch RN (1964). "John Crawford and his contribution to the doctrine of contagium vivum". Bacteriol Rev 28 (1): 87–96. PMC 441211. PMID 14130055.
- Manson P (1894). "On the nature and significance of the crescentic and flagellated bodies in malarial blood". Brit Med J 2 (4849): 1306–8. doi:10.1136/bmj.2.1771.1306. PMC 2405325. PMID 20755205.
- King AFA (1883). "Insects and disease, mosquitoes and malaria". Popular Sci. Monthly, Sep. 23: 644–658.
- WHO (2013). "Yellow fever". Fact sheet 2013.
- "A History of Mosquitoes in Massachusetts, by Curtis R. Best". Northeast Mosquito Control Association. Retrieved 2008-03-31.
- "World Mosquito Day 2010". Department for International Development. 20 August 2010. Archived from the original on 21 November 2012. Retrieved 21 November 2012.
- "Biography of Ronald Ross". The Nobel Foundation. Retrieved 2007-06-15.
- Capanna E (2006). "Grassi versus Ross: who solved the riddle of malaria?". Int Microbiol. 9 (1): 69–74. PMID 16636993.
- Grassi B, Bignami A, Bastianelli G (1899). "Ulteriore ricerche sul ciclo dei parassiti malarici umani sul corpo del zanzarone". Accad Lincei (8): 21–28.
- "Ross and the Discovery that Mosquitoes Transmit Malaria Parasites". CDC Malaria website. Archived from the original on 2 June 2007. Retrieved 2007-06-15.
- Seeman JI (2007). "The Woodward-Doering/Rabe-Kindler total synthesis of quinine: setting the record straight". Angew Chem Int Ed Engl. 46 (9): 1378–413. doi:10.1002/anie.200601551. PMID 17294412.
- Thayer W. (1898). Lectures on the malarial fevers. D.Appleton & Co., New York. ISBN 978-0-543-91236-7.
- Manson P (2002). "Experimental proof of the mosquito-malaria theory. 1900". Originally published in Br Med J 1900;2:949–951; reprint in: Yale J Biol Med 75 (2): 107–12. PMC 2588736. PMID 12230309.
- Manson PT (1901). "Experimental Malaria: Recurrence after Nine Months". Br Med J 2 (2115): 77. doi:10.1136/bmj.2.2115.77. PMC 2505910. PMID 20759742.
- Bignami A, Bastianelli G (1900). "Sulla inoculazione delle sangue di semiluna malariche d'uomo". Atti Soc Studi Malar 1: 15–20.
- Ross R, Thompson D (1910). "Some enumeration studies on malarial fever". Ann Trop Med Parasitol 4: 267–306.
- James SP, Tate P (1938). "Exo-erythrocytic schizogony in Plasmodium gallinaceum Brumpt, 1935". Parasitology 30: 128–138. doi:10.1017/S0031182000010891.
- Marchoux E (1926). "Paludisme". J. B. Bailliere, Paris.
- James SP (1931). "The use of plasmoquine in the prevention of malarial infections". Proc R Acad Sci Amst 34: 1424–1425.
- Huff CG, Bloom W (1935). "A Malarial Parasite Infecting All Blood and Blood-Forming Cells of Birds". J Infect Dis (The Journal of Infectious Diseases, Vol. 57, No. 3) 57 (3): 315–336. doi:10.1093/infdis/57.3.315. JSTOR 30088998.
- Fairley NH (1945). "Chemotherapeutic suppression and prophylaxis in malaria". Trans R Soc Trop Med Hyg 38 (5): 311–65. doi:10.1016/0035-9203(45)90038-1. PMID 20293965.
- Shute PG (1946). "Latency and long-term relapses in benign tertian malaria". Trans R Soc Trop Med Hyg 40 (2): 189–200. doi:10.1016/0035-9203(46)90056-9. PMID 20275230.
- Sapero JJ (1947). "New Concepts in the Treatment of Relapsing Malaria". Am J Trop Med Hyg 27 (3): 271–283.
- Garnham PCC (1947). "Exoerythrocytic schizogony in Plasmodium kochi laveran. A preliminary note". Trans R Soc Trop Med Hyg 40 (5): 719–22. doi:10.1016/0035-9203(47)90029-1. PMID 20243887.
- Shortt HE, Garnham PCC (1948). "Pre-erythrocytic stage in mammalian malaria parasites". Nature 161 (4082): 126. doi:10.1038/161126a0. PMID 18900752.
- Shortt HE, Fairley NH, Covell G, Shute PG, Garnham PCC (1948). "Pre-erythrocytic Stage of Plasmodium Falciparum". Br Med J 2 (4635): 1006–8, illust. doi:10.1136/bmj.2.3282.1006-c. PMC 2051640. PMID 15393036.
- Cogswell FB (1992). "The hypnozoite and relapse in primate malaria". Clin. Microbiol. Rev. 5 (1): 26–35. doi:10.1128/CMR.5.1.26. PMC 358221. PMID 1735093.
- Krotoski WA, Collins WE, Bray RS, Garnham PCC, Cogswell FB, Gwadz RW, Killick-Kendrick R, Wolf R, Sinden R, Koontz LC, Stanfill PS (1982). "Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection". Am J Trop Med Hyg 31 (6): 1291–3. PMID 6816080.
- Markus MB (2011). "Malaria: Origin of the Term "Hypnozoite"". J Hist Biol 44 (4): 781–6. doi:10.1007/s10739-010-9239-3. PMID 20665090.
- Vogel G (2013). "Malaria as a Lifesaving Therapy". Science 342: 686. PMID 24202157.
- Wagner-Jauregg J. (1931). "Verhütung und Behandlung der Progressiven Paralyse durch Impfmalaria". Handbuch der experimentellen Therapie, Ergänzungsband München.
- Frankenburg FR, Baldessarini RJ (2008). "Neurosyphilis, malaria, and the discovery of antipsychotic agents". Harv Rev Psychiatry. 16 (5): 299–307. doi:10.1080/10673220802432350. PMID 18803105.
- "The Nobel Prize in Physiology or Medicine 1927". The Nobel Foundation. Retrieved 2007-07-28.
- Brian Ross And Joseph Rhee (Jun 8, 2007). "Dr. Heimlich’s New ‘Maneuver’: Cure AIDS With Malaria". ABC News.
- Nierengarten, M. B. (2003). "Malariotherapy to treat HIV patients?". The Lancet Infectious Diseases 3 (6): 321. doi:10.1016/S1473-3099(03)00642-X.
- Finlay CJ. (1881). "El mosquito hipotéticamente considerado como agent de transmision de la fiebre amarilla". Anales de la Real Academia de Ciencias Médicas Físicas y Naturales de la Habana (18): 147-169.
- Reed W, Carroll J, Agramonte A (1901). "The Etiology of Yellow Fever". JAMA 36: 431–440.
- Sutter PS (2007). "Nature's agents or agents of empire? Entomological workers and environmental change during the construction of the Panama Canal". Isis 98 (4): 724–54. doi:10.1086/529265. PMID 18314643.
- Krafts K, Hempelmann E, Skórska-Stania A (2012). "From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy". Parasitol Res 11 (1): 1–6. doi:10.1007/s00436-012-2886-x. PMID 22411634.
- Hempelmann E. (2007). "Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors". Parasitol Res 100 (4): 671–6. doi:10.1007/s00436-006-0313-x. PMID 17111179.
- Jensen M, Mehlhorn H (2009). "Seventy-five years of Resochin in the fight against malaria". Parasitol Res 105 (3): 609–27. doi:10.1007/s00436-009-1524-8. PMID 19593586.
- Coatney GR (1963). "Pitfalls in a Discovery: The Chronicle of Chloroquine". Am J Trop Med Hyg. 12 (2): 121–8. PMID 14021822.
- Loeb RF, Clark WM, Coatney GR, Coggeshall LT, Dieuaide FR, Dochez AR, Hakansson EG, Marshall EK, Marvel SC, McCoy OR, Sapero JJ, Sebrell WH, Shannon JA, Carden GA (1946). "Activity of a new antimalarial agent, chloroquine (SN 7618)". J.Am.Med.Assoc. 130 (16): 1069–1070. doi:10.1001/jama.1946.02870160015006.
- Wellems TE, Plowe CV (2001). "Chloroquine-resistant malaria". J. Infect. Dis. 184 (6): 770–6. doi:10.1086/322858. PMID 11517439.
- Payne D (1987). "Spread of chloroquine resistance in Plasmodium falciparum". Parasitol. Today (Regul. Ed.) 3 (8): 241–6. doi:10.1016/0169-4758(87)90147-5. PMID 15462966.
- Snow RW, Trape JF, Marsh K (2001). "The past, present and future of childhood malaria mortality in Africa". Trends Parasitol. 17 (12): 593–7. doi:10.1016/S1471-4922(01)02031-1. PMID 11756044.
- Li Y, Wu Y (2010). "A golden phoenix arising from the herbal nest – A review and reflection on the study of antimalarial drug Qinghaosu". Frontiers of Chemistry in China 5 (4): 357–422. doi:10.1007/s11458-010-0214-5.
- Liao F (2009). "Discovery of Artemisinin (Qinghaosu)". Molecules 14 (12): 5362–5366. doi:10.3390/molecules14125362.
- Miller LH, Su X (2011). "Artemisinin: Discovery from the Chinese Herbal Garden". Cell 146 (6): 855–858.
- Chotivanich K, Sattabongkot J, Udomsangpetch R, Looareesuwan S, Day NP, Coleman RE, White NJ (2006). "Transmission-Blocking Activities of Quinine, Primaquine, and Artesunate". Antimicrob Agents Chemother 50 (6): 1927–30. doi:10.1128/AAC.01472-05. PMC 1479118. PMID 16723547.
- Weiyuan C (2009). "Ancient Chinese anti-fever cure becomes panacea for malaria". Bull World Health Organ 87 (10): 743–4. doi:10.2471/BLT.09.051009. PMC 2755319. PMID 19876540.
- Nosten F, White NJ (2007). "Artemisinin-based combination treatment of falciparum malaria". Am J Trop Med Hyg. 77 (6): 181–92. PMID 18165491.
- White NJ (2008). "Qinghaosu (artemisinin): the price of success". Science. 320 (5874): 330–334. doi:10.1126/science.1155165. PMID 18420924.
- Hale V, Keasling JD, Renninger N, Diagana TT (2007). "Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs". Am J Trop Med Hyg. 77 (6 Suppl): 198–202. PMID 18165493.
- Spielman, Andrew; D'Antonio, Michael (2002). Mosquito: The Story of Man's Deadliest foe. Hyperion. p. 131. ISBN 978-0-7868-8667-8..
- Parmakelis A, Russello MA, Caccone A, Marcondes CB, Costa J, Forattini OP, Sallum MA, Wilkerson RC, Powell JR (2008). "Historical analysis of a near disaster: Anopheles gambiae in Brazil". Am J Trop Med Hyg 78 (1): 176–8. PMID 18187802.
- Russell PF, West LS, Manwell RD, MacDonald G (1963). "Practical Malariology 2nd ed". Oxford University Press, London, New York, Toronto.
- Zeidler O (1874). "Verbindungen von Chloral mit Brom- und Chlorbenzol". Berichte der deutschen chemischen Gesellschaft 7 (2): 1180–1181. doi:10.1002/cber.18740070278.
- "The Nobel Prize in Physiology or Medicine 1948". The Nobel Foundation. Retrieved 2007-07-28.
- The Rockefeller Foundation (1944). Annual Report.
- Soper FL, Knipe FW, Casini G, Riehl LA, Rubino A (1947). Reduction of Anopheles Density Effected by the Preseason Spraying of Building Interiors with DDT in Kerosene, at Castel Volturno, Italy, in 1944–1945 and in the Tiber Delta in 1945 27 (1). pp. 177–200. PMID 20292226.
- Tognotti E (2009). "Program to Eradicate Malaria in Sardinia, 1946–1950". Emerg Infect Dis. 15 (9): 1460–6. doi:10.3201/eid1509.081317. PMC 2819864. PMID 19788815.
- James L. A. Webb, "The First Large-Scale Use of Synthetic Insecticide for Malaria Control in Tropical Africa: Lessons from Liberia, 1945–1962". Journal of the History of Medicine & Allied Sciences (2011) 66#3 pp 347-376
- Sadasivaiah S, Tozan Y, Breman JG (2007). "Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control?". Am. J. Trop. Med. Hyg. 77 (6): 249–63. PMID 18165500.
- Duchon S, Bonnet J, Marcombe S, Zaim M, Corbel V (2009). "Pyrethrum: a mixture of natural pyrethrins has potential for malaria vector control". Journal of Medical Entomology 46 (3): 516–22. doi:10.1603/033.046.0316. PMID 19496422.
- Vincke IH, Lips M (1948). "Un nouveau plasmodium d'un rongeur sauvage du Congo: Plasmodium berghei n.sp". Annales de la Société belge de médecine tropicale 28: 97–104.
- Hollingdale, Michael R.; Leland, Pamela; Leef, James L.; Beaudoin, Richard L. (April 1983). "The Influence of Cell Type and Culture Medium on the In vitro Cultivation of Exoerythrocytic Stages of Plasmodium berghei". The Journal of Parasitology 69 (2): 346–352.
- Davies, C. S.; Suhrbier, A. S.; Winger, L. A.; Sinden, R. E. (1989). "Improved techniques for the culture of the liver stages of Plasmodium berghei and their relevance to the study of causal prophylactic drugs". Acta Leidensia 58 (2): 97–113. PMID 2489396.
- Schuster, F. L. (2002). "Cultivation of Plasmodium spp". Clinical Microbiology Reviews 15 (3): 355–64. doi:10.1128/CMR.15.3.355-364.2002. PMC 118084. PMID 12097244.
- Trager W, Jensen JB (1976). "Human malaria parasites in continuous culture". Science 193 (4254): 673–5. doi:10.1126/science.781840. PMID 781840.
Schuster FL (2002). "Cultivation of Plasmodium spp". Clin Microbiol Rev. 15 (3): 355–64. doi:10.1128/CMR.15.3.355-364.2002. PMC 118084. PMID 12097244.
- Hempelmann E, Wilson RJM (1982). "Immunoprecipitation of malarial enzymes". Protozoology 29: 637.
- Ling IT, Cooksley S, Bates PA, Hempelmann E, Wilson RJM (1986). "Antibodies to the glutamate dehydrogenase of Plasmodium falciparum". Parasitology 92 (2): 313–24. doi:10.1017/S0031182000064088. PMID 3086819.
- Makler MT, Piper RC (2009). "Rapid malaria tests: where do we go after 20 years?". Am J Trop Med Hyg 81 (6): 921–6. doi:10.4269/ajtmh.2009.09-0202. PMID 19996417.
Bisoffi Z, Gobbi F, Angheben A, Van den Ende J (2009). "The Role of Rapid Diagnostic Tests in Managing Malaria". PLOS Medicine 6 (4): e1000063. doi:10.1371/journal.pmed.1000063. PMC 2667642. PMID 19399160.
- Antinori S, Galimberti L, Milazzo L, Corbellino M (2013). "Plasmodium knowlesi: The emerging zoonotic malaria parasite". Acta Tropica (125): 191–201.
- Alphonse Laveran Nobel Lecture: Protozoa as causes of disease
- Paul H Müller Nobel Lecture 1948: Dichloro-diphenyl-trichloroethane and newer insecticides
- Ronald Ross Nobel Lecture
- Julius Wagner-Jauregg Nobel Lecture: The Treatment of Dementia Paralytica by Malaria Inoculation
- Grassi versus Ross: Who solved the riddle of malaria?
- Malaria and the Fall of Rome
- Malaria Around the North Sea
- Malariasite: History
- Centers for Disease Control: History of Malaria